Role of FGF19 induced FGFR4 activation in the regulation of glucose
































The fibroblast growth factors (FGFs) family is 
composed of 22 members that are grouped into 7 
subfamilies [1].  Most FGF family members are 
considered to be paracrine factors, and have been shown 
to be involved in the processes of development, 
transformation, and angiogenesis [2-4].  However, the 
FGF19 subfamily members, which include FGF19, 21, 
and 23, have recently been shown to function in an 
endocrine manner and to regulate physiological 
processes that include glucose, lipid, and energy 
metabolism, as well as bile acid and serum phosphate 
homeostasis [5].  One key difference between the 
FGF19 subfamily and other FGF proteins is their weak 
affinity toward heparan sulfate of the pericellular space.  
This weak affinity allows FGF19 subfamily members to 
escape from the extracellular compartment into 
circulation and to function as endocrine hormones [5, 
6].  Whereas heparan sulfate is used by other FGFs to 
form high-affinity interactions with FGF receptors 
(FGFRs), the FGF19 subfamily members instead use 
single-transmembrane containing Klotho proteins to 


































sates for the reduced affinity of FGF19 subfamily 
members toward heparan sulfates and FGFRs [6].   
 
Two related Klotho proteins, αKlotho and βKlotho, 
both contain two homologous extracellular domains that 
share sequence homology to the β-glucosidase of 
bacteria and plants [7, 8].  FGF21 and FGF23 
selectively use βKlotho and αKlotho as co-receptors, 
respectively, while FGF19 can function through either 
co-receptor  in vitro [9].  The FGF23-αKlotho axis 
regulates systemic phosphate, calcium, and vitamin D 
homeostasis (Figure 1, [10]).  In addition, FGF23-
αKlotho is also involved in the control of aging.  Mice 
over-expressing  αKlotho protein live longer than 
normal mice and manifest a delay in many effects of old 
age, including weakening of the bone, clogging of the 
arteries and loss of muscle fitness [7].  Like FGF23, 
FGF19 can also activate FGFRs via αKlotho in vitro 
[11], however, the physiological significance of this 
observation is unclear because FGF19 and FGF23 do 
not appear to share overlapping phenotypes [12, 13].   




















































Therefore, determining whether the FGF19-αKlotho 
axis may also regulate phosphate and vitamin D 
homeostasis and play a role in controlling the aging 
process requires further study. 
 
Interactions between βKlotho and FGF19 or FGF21 as 
well as between βKlotho and FGFRs have been clearly 
demonstrated by several research groups [6, 9, 11, 14].  
Activation of FGFR isoforms 1c, 2c and 3c signaling by 
FGF19 or FGF21 only occurred when βKlotho is 
present, which confirms the requirement for βKotho as 
the co-receptor for these FGFs and is consistent with  
the ability of βKlotho to interact with these receptor 
isoforms [6, 14, 16].  FGFR isoforms 1b, 2b, and 3b are 
not activated by FGF19 or FGF21 in the presence of 
βKlotho presumably due to the inability of βKlotho to 
interact with these receptor isoforms [6, 14, 15].   
FGFR4 is not activated by FGF21 even though FGFR4 
interacts with βKlotho [14, 16].  However, FGFR4 can 
be activated by FGF19 in either the presence or absence 
of  βKlotho [16].  The unique βKlotho independent 
activity of FGF19 on FGFR4 is partly due to its residual 
affinity toward heparan sulfate, although its affinity is 
much weaker compared with canonical FGFs.   
 
One important consequence of the FGF19 subfamily’s 
reliance on α or βKlotho instead of heparan sulfates as 





























by the expression pattern of these co-receptor proteins.  
Since co-factor heparan sulfates are ubiquitous, 
canonical FGFs  will activate any tissue as long as their 
targeting FGFR isoforms are present.  In contrast, 
FGF19, 21 and 23 typically will only activate tissues 
where both their targeting FGFR isoforms and α or 
βKlotho are present.  For example, since βKlotho is 
primarily expressed in adipose tissue and liver, this 
expression pattern limits the potential target tissues for 
FGF21 action.  Since the predominant FGFR residing in 
the liver is FGFR4, which can not be activated by 
FGF21, the direct target tissue for FGF21 has been 
proposed to be further limited to only adipose tissue 
where FGFR1c and 2c are the major receptors [14, 15].  
In vivo experiments provided support for this 
hypothesis.  Specifically, when skeletal muscle, adipose 
tissue, kidney and liver were excised from mice treated 
with recombinant FGF21, elevated phospho-ERK 
levels, which represents activation of FGFR signaling, 
were only observed in lysates of adipose tissue [14, 15].  
  
Unlike FGF21, FGF19 is able to activate FGFR4 in 
addition to FGFRs 1c, 2c, and 3c; therefore, the liver is 
potentially a direct target tissue of FGF19 in addition to 
adipocytes.  Consistent with this hypothesis, ERK 
phophorylation levels increased in both mouse adipose 
tissue and liver after recombinant FGF19 treatment [14].  
In addition,  it has been proposed that FGF19 activates 
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levels and that this inhibition is mediated through SHP 
and HNF4α [17, 18]. Cyp7A1 encodes cholesterol 7 α-
hydroxylase, which is the key enzyme in the bile acid 
biosynthesis pathway [18].  Decreased Cyp7A1 mRNA 
levels will lead to reduced production of bile acid from 
cholesterol.  In FGFR4 knockout mice, FGF19 no 
longer affects Cyp7A1 mRNA levels in the liver, 
confirming the role of FGFR4 signaling in mediating 
FGF19 inhibition of Cyp7A1 expression [18].  Genetic 
ablation of βKlotho gene in mice increases bile acid 
synthesis and Cyp7A1 expressing level, probably due to 
the weakened activation of liver FGFR4 [19].  These 
results are consistent with a role for FGF19 in the 
regulation bile acid synthesis from liver.   
 
Recently, there has been new evidence suggesting that 
FGFR4 is also involved in phenotypes related to the 
metabolic syndrome.  For example, FGFR4-deficient 
mice that were fed a regular diet displayed hyper-
lipidemia, glucose intolerance and insulin resistance as 
well as increased weight gain compared with wild type 
litter mates.  Restoration of FGFR4 in the livers of 
FGFR4 deficient mice decreased plasma lipid levels 
[20].  FGFR4 has also been implicated in insulin 
regulation with FoxO1 as a key node in integrating the 
FGF and insulin signaling pathways [21].  Since 
recombinant FGF19 improves dyslipidemia and insulin 
sensitivity and reduces adiposity in diet-induced obese 
(DIO) mice, it is important to understand how liver and 
FGFR4 contribute to lipid and glucose homeostasis in 
addition to bile acid biosynthesis regulation.  However, 
studying the contribution of the liver FGF19/FGFR4 
pathway is complicated by the fact that FGF19 can also 
induce signaling in other tissues.  The ability of FGF19 
to activate both adipose tissue and liver, makes it 
difficult to assess the contribution of each target tissue 
individually.   
 
It was known that the C-terminal tail of FGF19 is 
important for co-receptor interaction [9].  Amino acid 
sequence alignments demonstrate the absence of the 
FGF19 C-terminal βKlotho binding domain in 
canonical FGFs such as FGF1 and FGF2, which do not 
require co-receptors such as βKlotho.  It is conceivable 
that the C-terminal tail in FGF19 was acquired during 
evolution to compensate for its dramatically weakened 
affinity toward heparan sulfates.  However, the fact that 
FGF19 can activate FGFR4 signaling in the absence of 
βKlotho suggests that at least for FGFR4, the affinity 
between FGF19 and heparan sulfates might be 
sufficient to induce receptor activation under certain 
conditions.  If that is the case, deletion of the C-terminal 
βKlotho-binding domain should not affect its ability to 
activate FGFR4 because the predicted heparan sulfates 
interacting regions are not located in the C-terminal tail 
of FGF19 [6].  We therefore constructed and purified a 
truncated FGF19, FGF19dCTD, without its C-terminal 
βKlotho-interacting domain and characterized its 
activity  in vitro and in vivo.  An in vitro receptor 
specificity assay confirmed that FGF19dCTD is still 
able to activate FGFR4 but not other FGFRs even in the 
presence of βKlotho.  FGF19dCTD thus became an 
FGFR4 specific activator.  In mice injected with 
FGF19dCTD, ERK phosphorylation was observed only 
in liver (where FGFR4 expression is predominant) but 
not in the fat tissues (where FGFR1c and 2c expressions 
are predominant).  Consistent with increased liver ERK 
phosphorylation after FGF19dCTD treatment, liver 
CYP7A1 mRNA expression levels were also suppressed 
in mice injected with FGF19dCTD.  However, the 
ability to reduce plasma glucose levels and to improve 
glucose tolerance has been lost with FGF19dCTD, 
suggesting a limited contribution from direct activation 
of FGFR4 toward glucose regulation.  Since other than 
liver,  βKlotho is predominantly expressed in adipose 
tissue and pancreas, it is reasonable to speculate that 
direct activation of these tissues by FGF19 is the major 
mechanism contributing to the regulation of glucose 
homeostasis. 
 
There are still unanswered questions regarding the 
mechanisms by which FGF19 and FGF21 regulate 
glucose metabolism and improve insulin sensitivity; 
however, data from a recently published study suggest 
that adipocytes may play an important role in these 
processes.  Both FGF19 and FGF21 have been shown to 
induce glucose uptake into adipocytes, and FGF21 
treatment also resulted in acute suppression of 
adipocyte lipolysis and reduction in plasma free fatty 
acid levels [14, 22, 23].  These effects may directly 
contribute to the improvement in glucose regulation and 
insulin sensitivity.  Whether other mechanisms 
associated with adipose tissue also contribute remains to 
be explored.  The role of liver in glucose regulation 
remains an open question.  It has been shown that β-
oxidation in liver was increased in FGF19 transgenic 
mice, which may have led to improvement in metabolic 
conditions and glucose homeostasis [12].  Recent 
evidence has also suggested that FGF21 may directly 
act on liver to regulate hepatic gluconeogenesis [24, 
25].  Although our results suggest that liver FGFR4 
activation may not be important in these activities, the 
roles for other liver-expressed FGFRs need to be further 
explored.  Alternatively, if liver is not a direct target 
tissue for FGF19 or FGF21, the identification of 
secondary signals emanating from other tissues to liver 
will be important in elucidating the overall mechanism 
that leads to the beneficial changes observed for this 
subfamily of FGF molecules. 
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group of molecules that are being actively studied.   
Emerging data in recent years have allowed us to begin 
making connections between physiological phenotypes 
and the molecular details, such as receptor specificity 
and co-factor requirements.  In the future, new findings 
should allow us to fill in knowledge gaps and to gain 
better insight into the mechanisms of action of FGF19 
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